Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs Treatment for Serious and Critical COVID-19 Pneumonia
NCT04269525Phase 2Unknown
- Start
- Feb 2020
- Primary completion
- Dec 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord derived mesenchymal stem cells in COVID-19 pneumonia. Primary endpoint: Oxygenation index at Day 14. Status: unknown.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04269525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269525.